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Background: The BRIM-3 trial showed improved progression-free survival (PFS) and overall survival (OS) for vemurafenib
compared with dacarbazine in treatment-naive patients with BRAFV600 mutation–positive metastatic melanoma. We present
final OS data from BRIM-3.
Patients and methods: Patients were randomly assigned in a 1 : 1 ratio to receive vemurafenib (960mg twice daily)
or dacarbazine (1000mg/m2 every 3weeks). OS and PFS were co-primary end points. OS was assessed in the intention-to-treat
population, with and without censoring of data for dacarbazine patients who crossed over to vemurafenib.
Results: Between 4 January 2010 and 16 December 2010, a total of 675 patients were randomized to vemurafenib (n¼ 337)
or dacarbazine (n¼ 338, of whom 84 crossed over to vemurafenib). At the time of database lock (14 August 2015), median OS,
censored at crossover, was significantly longer for vemurafenib than for dacarbazine {13.6months [95% confidence interval (CI)
12.0–15.4] versus 9.7months [95% CI 7.9–12.8; hazard ratio (HR) 0.81 [95% CI 0.67–0.98]; P¼ 0.03}, as was median OS without
censoring at crossover [13.6months (95% CI 12.0–15.4) versus 10.3months (95% CI 9.1–12.8); HR 0.81 (95% CI 0.68–0.96);
P¼ 0.01]. Kaplan–Meier estimates of OS rates for vemurafenib versus dacarbazine were 56% versus 46%, 30% versus 24%,
21% versus 19% and 17% versus 16% at 1, 2, 3 and 4 years, respectively. Overall, 173 of the 338 patients (51%) in the dacarbazine
arm and 175 of the 337 (52%) of those in the vemurafenib arm received subsequent anticancer therapies, most commonly
ipilimumab. Safety data were consistent with the primary analysis.
Conclusions: Vemurafenib continues to be associated with improved median OS in the BRIM-3 trial after extended follow-up.
OS curves converged after3 years, likely as a result of crossover from dacarbazine to vemurafenib and receipt of subsequent
anticancer therapies.
ClinicalTrials.gov: NCT01006980.
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Introduction
Several new treatment options for metastatic melanoma have
emerged over the last 5 years, including small-molecule inhibitors of
BRAF and MEK and monoclonal antibodies targeting programmed
death (PD-1) and cytotoxic T-lymphocyte-associated antigen 4
(CTLA-4) [1–12]. These agents have revolutionized the treatment
of metastatic melanoma, but limited data are available so far
regarding long-term outcomes.
Activating mutations in the BRAF oncogene are the most
frequent genetic alterations in melanoma, occurring in 50% of
melanomas [13–16]. BRAF mutations result in constitutive
activation of the BRAF kinase and, consequently, downstream
activation of the mitogen-activated protein kinase (MAPK)
signalling pathway that regulates cell proliferation, growth and
differentiation [13, 16].
Vemurafenib is an inhibitor of oncogenic BRAF kinase and
was the first BRAF inhibitor to be tested in a phase III trial.
The pivotal BRIM-3 study was a randomized phase III study that
compared vemurafenib with dacarbazine in patients with
previously untreated unresectable stage IIIC or stage IV
melanoma harbouring BRAFV600 mutations [1, 17]. The prespeci-
fied interim analysis of the BRIM-3 study (data cut-off date,
30 December 2010) demonstrated improved median progression-
free survival [PFS; hazard ratio (HR) 0.26; 95% confidence
interval (CI) 0.20–0.33; P< 0.001] and overall survival (OS;
HR 0.37; 95% CI 0.26–0.55; P< 0.001) for vemurafenib compared
with dacarbazine [1]. After extended follow-up (data cut-off date,
1 February 2012), vemurafenib remained associated with
improved PFS (HR 0.38; 95% CI 0.32–0.46; P< 0.001) and OS
(HR 0.70; 95% CI 0.57–0.87; P< 0.001) compared with dacarba-
zine [17]. Previously, we reported landmark OS analysis at 1 year.
Here, we report final OS data from the BRIM-3 study, including
landmark analyses at 3 and 4 years (database lock 14 August
2015).
Patients and methods
Study design
The BRIM-3 study was a multicentre, randomized, open-label, parallel-
arm study. Detailed methods for the BRIM-3 study have previously been
reported [1, 17]. Briefly, eligible patients were age18 years, had previ-
ously untreated, unresectable stage IIIC or stage IV melanoma with a
BRAFV600 mutation, life expectancy3 months, Eastern Cooperative
Oncology Group performance status (ECOG PS) 0 or 1 and adequate
haematological, hepatic and renal function.
Patients were randomly assigned in a 1 : 1 ratio to receive either
vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg/m2 as
an intravenous infusion every 3 weeks). Randomization was stratified ac-
cording to American Joint Committee on Cancer stage (IIIC, M1a, M1b
or M1c), ECOG PS (0 or 1), geographic region (North America, Western
Europe, Australia/New Zealand or other region) and serum lactate de-
hydrogenase (LDH) level (normal or elevated). Treatment was adminis-
tered until disease progression.
The protocol was approved by institutional review boards at each par-
ticipating institution and the study was conducted in accordance with
the principles of the Declaration of Helsinki and International
Conference on Harmonization Good Clinical Practice guidelines. All
patients provided written informed consent.
Outcomes
The co-primary end points were OS, defined as the time from randomisa-
tion to death from any cause, and PFS, defined as the time from random-
isation to documented disease progression or death. Secondary end
points included confirmed response according to Response Evaluation
Criteria In Solid Tumors, version 1.1, time to response, duration of re-
sponse and safety and tolerability. Final OS results and long-term safety
and tolerability are reported; PFS and secondary end points have been
reported elsewhere [1, 17].
Statistical analysis
Enrolment of 680 patients would provide power of 80% to detect an HR
of 0.65 for OS with an a level of 0.045 and a power of 90% to detect an
HR of 0.55 for PFS with an a level of 0.005. The final OS analysis was
planned after 196 deaths had occurred.
A planned interim analysis of OS occurred on 14 January 2011 [1].
The data safety monitoring board recommended release of the results
due to compelling efficacy and recommended that patients in the dacar-
bazine arm be allowed to cross over to vemurafenib. The protocol was
amended to allow crossover on 14 January 2011; disease progression on
dacarbazine was not required in order for patients to cross over to
vemurafenib.
The database lock date for the final OS analysis was 14 August 2015.
OS was assessed in the intention-to-treat (ITT) population, with and
without censoring of data for patients in the dacarbazine arm who
crossed over to vemurafenib. OS and PFS were estimated using the
Kaplan–Meier method. Sensitivity analyses were also carried out using
five scenarios of assumed benefit for vemurafenib after crossover (reduc-
tion in the risk for death by 20%, 30%, 40%, 50% or 60%). For each scen-
ario, survival after crossover was imputed to be the observed survival
after crossover reduced by the assumed benefit in survival attributable to
vemurafenib after crossover.
The ITT population included all randomly assigned patients and the
safety population included all patients who received a study drug.
Prespecified subgroup analyses were carried out according to age, sex,
ECOG PS, tumour stage, LDH level at baseline and geographic region.
Results
Patients
Between 4 January 2010 and 16 December 2010, 675 eligible pa-
tients were enrolled and randomly assigned to receive vemurafe-
nib (n¼ 337) or dacarbazine (n¼ 338). As previously reported
[1, 17], baseline characteristics were well balanced between
treatment arms (Table 1).
At the time of database lock (14 August 2015), all patients in both
treatment arms had discontinued from the study, primarily because
of disease progression (Figure 1). The median duration of follow-
up for the ITT population was 13.4 months (range 0.4–59.6) for
patients in the vemurafenib arm and 9.2 months (range 0–56.2) for
patients in the dacarbazine arm. Among 66 patients in the vemura-
fenib arm and 79 patients in the dacarbazine arm who were known
not to have died at the time of database lock, the median follow-up
duration was 49.9 months (range 0.4–59.6) and 42.8 months (range
0–56.2), respectively.
A total of 84 of 338 patients in the dacarbazine arm crossed
over to vemurafenib treatment. The median duration of vemura-
fenib exposure was similar between patients initially randomized
to receive vemurafenib (median 6.6 months; range 0–57.1) and
Original article Annals of Oncology
2582 | Chapman et al. Volume 28 | Issue 10 | 2017
those who crossed over from dacarbazine (median 6.6 months;
range 0.7–47.3). Overall, 173 of the 338 patients (51%) in the
dacarbazine arm and 175 of the 337 (52%) of those in the vemur-
afenib arm received subsequent anticancer therapies (Table 2),
most commonly ipilimumab [88/338 (26%) and 93/337 (28%),
respectively].
Overall survival
At the time of database lock, 271 patients in the vemurafenib arm
and 259 in the dacarbazine arm had died. In the ITT population,
median OS was significantly longer for vemurafenib than for
dacarbazine, with or without censoring of data for dacarbazine
patients who crossed over to vemurafenib (Figure 2). Median OS,
censored at crossover, was 13.6 months (95% CI 12.0–15.4)
for vemurafenib compared with 9.7 months (95% CI 7.9–12.8)
for dacarbazine [HR 0.81 [95% CI 0.7–1.0]; P¼ 0.03]. Median
OS without censoring at crossover was 13.6 months (95% CI
12.0–15.4) for vemurafenib compared with 10.3 months (95% CI
9.1–12.8) for dacarbazine [HR 0.81 (95% CI 0.7–1.0); P¼ 0.01].
Landmark OS rates at 1, 2, 3 and 4 years (without censoring at
crossover) were 55.7%, 30.2%, 20.8% and 17.0%, respectively, in
the vemurafenib arm, and 46.0%, 24.5%, 18.9% and 15.6%,
respectively, in the dacarbazine arm. Sensitivity analyses showed
significant OS benefit for vemurafenib over dacarbazine regard-
less of the magnitude of assumed benefit of vemurafenib after
crossover.
OS benefit for vemurafenib over dacarbazine was greatest in
the following subgroups: age 65 years; stage M1c disease; ele-
vated baseline LDH level; ECOG PS of 1 and no prior adjuvant
therapy. In the vemurafenib group, median OS was longer in pa-
tients with an ECOG PS of 0 than in those with an ECOG PS of 1
[16.8 (95% CI 14.5–20.2) versus 10.0 (95% CI 8.2–11.5) months],
and in those with normal versus elevated baseline LDH level
[18.1 (95% CI 15.0–21.5) versus 9.6 (95% CI 8.3–12.0) months]
(Figure 3). Similarly, in the dacarbazine group, median OS was
longer in patients with ECOG PS of 0 versus 1 [14.1 (95% CI
11.5–17.3) versus 6.1 (95% CI 4.4–7.9) months], and those with
normal versus elevated LDH [16.9 (95% CI 14.0–18.9) versus
5.8 (4.6–7.1) months] (Figure 3).
A descriptive summary of baseline disease characteristics of
patients alive at the 3- and 4-year landmarks shows that these
patients were more likely to have had favourable prognostic
characteristics at baseline, including normal LDH level, ECOG
PS of 0 and stage M1a/b disease, compared with the ITT popula-
tion (supplementary Table S1, available at Annals of Oncology
online). The survival benefit associated with vemurafenib in
long-term survivors (ie, patients alive at 3 and 4 years) was most
pronounced in patients aged65 years and in patients
with3 metastatic sites at baseline.
Patients without progression on vemurafenib
At the time of database lock, 36 of the 336 patients in the vemura-
fenib arm had not experienced disease progression. Most of these
patients had an ECOG PS of 0 [27 patients (75%)], M1c disease
[22 patients (61%)] and normal LDH levels [21 patients (58%)]
at baseline (supplementary Table S1, available at Annals of
Oncology online). The median duration of treatment with vemur-
afenib for these 36 patients was 24.0 months (range 0.4–57.1).
Reasons for treatment discontinuation were death (n¼ 7),
adverse event (AE) (n¼ 6), refused treatment (n¼ 4), withdrawal
of consent (n¼ 3) and other (n¼ 16). Of the 16 patients who
discontinued for other reasons, 10 were rolled over into a vemur-
afenib extension study (ClinicalTrials.gov ID, NCT01739764).
Neither median PFS nor OS was estimable.
Post-progression treatment with BRAF or MEK
inhibitors following vemurafenib treatment
Among patients randomized to receive vemurafenib, 20 received
post-progression anticancer treatment with a BRAF and/or MEK
inhibitor. The median OS in this small subset of patients was
36.0 months (95% CI 18.0–not estimable).
Safety
The safety profile of vemurafenib was similar to profiles seen in
previous publications (Tables 3 and 4) [1, 17] Patients initially as-
signed to the dacarbazine arm who crossed over to vemurafenib
were included in the vemurafenib arm for safety analyses.
A total of 334 of 336 patients (99%) in the vemurafenib arm and
266 of 287 patients (93%) in the dacarbazine arm reported at least
one AE. The most common AEs (occurring in20% of patients)
in the vemurafenib arm were rash, arthralgia, alopecia, fatigue,
photosensitivity reaction, nausea, diarrhoea, headache, hyperkera-
tosis, skin papilloma, pruritus, dry skin, decreased appetite, pain in
Table 1. Baseline demographics and clinical characteristics
Characteristic Dacarbazine
(n5338)
Vemurafenib
(n5337)
Median age (range), years 52 (17–86) 56 (21–86)
Male 181 (54) 200 (59)
White race 338 (100) 333 (99)
Geographic region
Australia/New Zealand 38 (11) 39 (12)
North America 86 (25) 86 (26)
Western Europe 203 (60) 205 (61)
Other 11 (3) 7 (2)
ECOG PS
0 230 (68) 229 (68)
1 108 (32) 108 (32)
LDH level
Normal (ULN) 142 (42) 142 (42)
Elevated (>ULN) 196 (58) 195 (58)
Disease stage
Unresectable IIIC 13 (4) 20 (6)
M1a 40 (12) 34 (10)
M1b 65 (19) 62 (18)
M1c 220 (65) 221 (66)
Reproduced with permission from Chapman PB et al. N Engl J Med 2011;
364: 2507–2516, Copyright Massachusetts Medical Society.
Unless otherwise indicated, all data are n (%).
ECOG PS, Eastern Cooperative Oncology Group performance status;
LDH, lactate dehydrogenase; ULN, upper limit of normal.
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extremity, pyrexia, vomiting and squamous cell carcinoma of the
skin (Table 3). The most common AEs (occurring in20% of pa-
tients) in the dacarbazine arm were nausea, fatigue, vomiting and
constipation (Table 3). A summary of all AEs by treatment arm
and grade can be found in the supplement (supplementary Tables
S2 and S3, available atAnnals of Oncology online).
Serious AEs were reported in 165 of 336 patients (49%) in the
vemurafenib arm and 52 of 287 patients (18%) in the dacarbazine
arm (Table 4). Squamous cell carcinoma of the skin was reported in
66 of 336 patients (20%) in the vemurafenib group, compared with
2 of 287 patients (<1%) in the dacarbazine group; keratoacanthoma
was reported in 36 of 336 patients (11%) in the vemurafenib group
and 3 of 287 patients (1%) in the dacarbazine group (Table 4).
Treatment was discontinued because of AEs in 25 of 336 pa-
tients (7%) in the vemurafenib group and 5 of 287 patients (2%)
in the dacarbazine group. AEs resulting in discontinuation in the
vemurafenib arm included arthralgia (n¼ 3), dysphagia (n¼ 2),
blood bilirubin increased (n¼ 2), rash (n¼ 2) and thrombocyto-
penia, cognitive disorder, dehydration, gait disturbance, myocar-
dial infarction, pneumonia, fatigue, gastro-oesophageal reflux
disease, choking, general physical health deterioration, blood cre-
atine phosphokinase increased, myoglobin blood increased, toxic
skin eruption, renal impairment, myalgia, conjunctival hyper-
aemia, Stevens-Johnson syndrome, oesophageal pain, uveitis,
diplopia, seizure, pancreatitis, pleural effusion, pleuritic pain,
atrial fibrillation, scleritis, acute hepatitis, cyanosis and peripheral
neuropathy in 1 patient each. AEs resulting in discontinuation in
the dacarbazine arm included hypotension, dyspnoea, pleural
effusion, nausea, vomiting, cerebrovascular accident and
pulmonary embolism in one patient each.
Discussion
The final OS analysis of the BRIM-3 trial shows that vemurafenib
continues to be associated with improved OS compared with
dacarbazine after long-term follow-up, though the benefits need
Screened
N = 2107
Randomized
N = 675
Dacarbazine
n = 338
Vemurafenib
n = 337
Screening failure
N = 1432
Discontinued study
n = 293 (100%)
Reason, n (%)
• Progression, 218 (74.4)
• Death, 12 (4.1)
• Withdrawal of consent, 6 (2.1)
• Refuse treatment, 6 (2.1)
• Adverse event, 5 (1.7)
• Protocol violation, 3 (1.0)
• Other, 43 (14.7)
Discontinued study
n = 336 (100%)
Reason, n (%)
• Progression, 257 (76.5)
• Adverse event, 25 (7.4)
• Death, 13 (3.9)
• Refuse treatment, 9 (2.7)
• Withdrawal of consent, 4 (1.2)
• Protocol violation, 2 (<1.0)
• Other, 26 (7.7)
Treated with
dacarbazine
n = 293
Treated with
vemurafenib
n = 336 
Figure 1. CONSORT diagram.
Table 2. Subsequent therapies in2% of patients in either arm
Subsequent therapies, n (%) Dacarbazine
(n5338)
Vemurafenib
(n5337)
Any subsequent anticancer therapy 173 (51) 175 (52)
Ipilimumab 88 (26) 93 (28)
Dacarbazine/temozolomide 28 (8) 64 (20)
Vemurafeniba 39 (12) 23 (7)
Other chemotherapy 46 (14) 24 (7)
Dabrafenib 7 (2) 7 (2)
BRAF inhibitor NOS 13 (4) 1 (<1)
Trametinib 7 (2) 5 (2)
aCommercially available vemurafenib or expanded access.
NOS, not otherwise specified.
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No. of patients at risk
Vem (n = 337)
DTIC (n = 338)
13.6 (12.0–15.4)
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Figure 2. Kaplan–Meier curves for OS (without censoring at crossover) in the ITT population. CI, confidence interval; DTIC, dacarbazine;
ITT, intention-to-treat; OS, overall survival; Vem, vemurafenib.
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Figure 3. Kaplan–Meier curves for OS (without censoring at crossover) for patients with (A) ECOG PS 0, (B) ECOG PS 1, (C) LDH level normal
and (D) LDH level elevated. CI, confidence interval; DTIC, dacarbazine; ECOG PS, Eastern Cooperative Oncology Group performance status;
LDH, lactate dehydrogenase; OS, overall survival. Vem, vemurafenib.
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to be balanced against toxicities. After long-term follow-up of the
BRIM-3 study, the safety profile of vemurafenib was similar to
that observed in earlier analyses, with no new safety signals iden-
tified [1, 17]. A plateau in the OS curves was observed be-
yond3 years, suggesting that patients who survive this long are
likely to have good outcomes. However, convergence of OS
curves for vemurafenib and dacarbazine was observed beginning
around the same time (3 years), with a plateau observed in both
groups. Interpretation of this convergence is confounded by early
crossover of patients from dacarbazine to vemurafenib (25% of
patients) and receipt of subsequent treatments (50% of patients
in each arm). It is unclear to what extent the OS tail may be influ-
enced by subsequent treatment with ipilimumab (received by
around one-quarter of patients in each group) and other sub-
sequent anticancer treatments. It is of interest that a similar
plateau in OS beyond3 years has also been observed with
ipilimumab [18].
Given the extent of crossover and subsequent treatment, it is
difficult to determine the contribution of vemurafenib to long-
term OS outcomes in subsets of patients defined by known prog-
nostic factors for survival. A summary of baseline characteristics
of long-term survivors (i.e. patients alive at 3 and 4 years) shows
that these patients were more likely to have good baseline prog-
nostic factors (ECOG PS 0, LDH normal, lower disease stage)
compared with the ITT population. Comparisons between treat-
ment groups suggest that survival benefit with vemurafenib ver-
sus dacarbazine was more pronounced in patient subgroups
defined by poor prognostic factors [i.e. older age (65 years) and
greater disease burden (3 metastatic sites)]. Interpretation of
these data is limited by the small numbers of patients.
Vemurafenib showed a survival benefit over dacarbazine in the
subset of patients with poor prognostic characteristics (ECOG PS
1 or elevated serum LDH). There was no detectable long-term OS
benefit from vemurafenib versus dacarbazine among patients
with more favourable survival characteristics (ECOG PS 0 or nor-
mal serum LDH). The lack of survival benefit in patients with fa-
vourable prognostic characteristics was not explained by a higher
rate of crossover. Instead, survival rates reported here likely re-
flect the long-term outcomes that can be expected in the current
era of available treatments for metastatic melanoma.
The BRIM-3 trial ushered in the era of targeted therapy against
mutated BRAF in melanoma. Since the approval of vemurafenib
monotherapy in 2011, the treatment landscape for BRAF-
mutated metastatic melanoma has changed considerably.
Combined BRAF and MEK inhibition offers more complete in-
hibition of MAPK signalling, and the combinations of dabrafenib
plus trametinib and cobimetinib plus vemurafenib have both
demonstrated improved response rates, PFS and OS compared
with BRAF inhibitor monotherapy [2, 5–7]. The dabrafenib plus
trametinib and cobimetinib plus vemurafenib combinations
were approved by the US Food and Drug Administration for the
first-line treatment of patients with BRAF-mutated metastatic
melanoma in 2014 and 2015, respectively, and by the European
Medicines Agency in 2015. Long-term OS results for these com-
binations are not yet available, but it is anticipated that the pla-
teau in the OS curves will be higher than the plateau seen in this
first monotherapy trial with a BRAF inhibitor.
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regardless of attribution to study drug
AEs, n (%) Dacarbazine
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Original article Annals of Oncology
2586 | Chapman et al. Volume 28 | Issue 10 | 2017
Funding
This work was supported by F. Hoffmann-La Roche Ltd. There
are no grant numbers associated with this funding. The authors
also acknowledge partial support from an NCI Cancer Center
Support Grant (CCSG, P30 CA08748).
Disclosure
PBC: consultant or advisory role, Roche/Genentech, LICR
Research, Merck, Rgenix and Scancel, honoraria,
GlaxoSmithKline; CR: consultant or advisory role, Bristol-
Myers Squibb, GlaxoSmithKline, Novartis, Amgen, Merck and
Roche; JL: consultant or advisory role, Roche/Genentech, MSD,
Novartis, Pfizer, GlaxoSmithKline and Bristol-Myers Squibb, re-
search funding (institution), MSD, Novartis, Pfizer and Bristol-
Myers Squibb; JBH: consultant or advisory role, Roche/
Genentech, Novartis, Pfizer, MSD, Bristol-Myers Squibb and
Neon, honoraria, Roche/Genentech, Novartis, Pfizer and Neon,
research funding (institution), MSD, Bristol-Myers Squibb and
GlaxoSmithKline; AR: consultant or advisory role, Roche,
Pfizer, Merck and Amgen, stock or other ownership,
Compugen, CytomX, Five Prime and Kite Pharma; DH:
research funding, Bristol-Myers Squibb, MSD and
GlaxoSmithKline; OH: consultant or advisory role and honora-
ria, Amgen, Novartis, Bristol-Myers Squibb and Merck, speak-
ers’ bureau, Bristol-Myers Squibb, Novartis, Genentech and
Amgen, research funding, AstraZeneca, Bristol-Myers Squibb,
Celldex, Genentech, Immunocore, Incyte, Merck, Merck
Serono, Medimmune, Novartis, Pfizer, Rinat and Roche; PAA:
consultant or advisory role, Roche/Genentech, MSD, Ventana,
Novartis, Amgen, Bristol-Myers Squibb and Array, research
funding, Roche, Bristol-Myers Squibb and Ventana; AT: con-
sultant or advisory role, Agenus, Lytrix and Merck; PL: consul-
tant or advisory role, Roche, Bristol-Myers Squibb, Merck,
Novartis, GlaxoSmithKline, Amgen and Chugai, speakers’ bur-
eau, Roche, GlaxoSmithKline, Merck, Bristol-Myers Squibb and
Chugai, investigator, GlaxoSmithKline, Bristol-Myers Squibb,
Amgen and Novartis; RD: consultant or advisory role, Novartis,
MSD, Bristol-Myers Squibb, Roche, GlaxoSmithKline and
Amgen, research funding, Novartis, MSD, Bristol-Myers
Squibb, Roche and GlaxoSmithKline; JAS: consultant or advi-
sory role and honoraria, Roche/Genentech; KTF: consultant or
advisory role and honoraria, Roche/Genentech; IChang: current
employment, stock ownership, honoraria, consultant or advi-
sory role, speakers’ bureau, travel, accommodations or expenses
and patents, Genentech; SC: current employment, Genentech,
stock ownership, Roche, Gilead Sciences, Teva, Celgene and
Johnson & Johnson; ICaro: current employment and stock own-
ership, Genentech/Roche; AH: consultant or advisory role and
honoraria, Roche, Amgen, Bristol-Myers Squibb, Celgene, Eisai,
GlaxoSmithKline, Medimmune, Mela Sciences, Merck Serono,
MSD/Merck, Novartis and Oncosec, research funding, Roche,
Amgen, Bristol-Myers Squibb, Celgene, Eisai, GlaxoSmithKline,
Mela Sciences, Merck Serono, MSD/Merck, Novartis and
Oncosec; GAM: consultant or advisory role, Provectus, research
funding, Pfizer, Celgene and Ventana, travel, accommodation
or expenses, Roche and Novartis.
References
1. Chapman PB, Hauschild A, Robert C et al. Improved survival with
vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med
2011; 364: 2507–2516.
2. Larkin J, Ascierto PA, Dre´no B et al. Combined vemurafenib and cobi-
metinib in BRAF-mutated melanoma. N Engl J Med 2014; 371:
1867–1876.
3. Hauschild A, Grob J-J, Demidov LV et al. Dabrafenib in BRAF-mutated
metastatic melanoma: a multicentre, open-label, phase 3 randomised
controlled trial. Lancet 2012; 380: 358–365.
4. Masuda S, Izpisua Belmonte JC. Trametinib for patients with advanced
melanoma. Lancet Oncol 2012; 13: e409–e410.
5. Long GV, Stroyakovskiy D, Gogas H et al. Combined BRAF and MEK in-
hibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014;
371: 1877–1888.
6. Robert C, Karaszewska B, Schachter J et al. Improved overall survival in
melanoma with combined dabrafenib and trametinib. N Engl J Med.
2015; 372: 30–39.
7. Long GV, Stroyakovskiy D, Gogas H et al. Dabrafenib and trametinib
versus dabrafenib and placebo for Val600 BRAF-mutant melanoma:
a multicentre, double-blind, phase 3 randomised controlled trial. Lancet
2015; 386: 444–451.
8. Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipili-
mumab in patients with metastatic melanoma. N Engl J Med 2010; 363:
711–723.
9. Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab
in advanced melanoma. N Engl J Med 2015; 372: 2521–2532.
10. Robert C, Long GV, Brady B et al. Nivolumab in previously untreated
melanoma without BRAF mutation. N Engl J Med 2015; 372: 320–330.
11. Weber JS, D’Angelo SP, Minor D et al. Nivolumab versus chemotherapy
in patients with advanced melanoma who progressed after anti-CTLA-4
treatment (CheckMate 037): a randomised, controlled, open-label, phase
3 trial. Lancet Oncol 2015; 16: 375–384.
12. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and
ipilimumab or monotherapy in untreated melanoma. N Engl J Med
2015; 373: 23–34.
13. Ascierto PA, Kirkwood JM, Grob J-J et al. The role of BRAF V600 muta-
tion in melanoma. J Transl Med 2012; 10: 85.
14. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human
cancer. Nature 2002; 417: 949–954.
15. Curtin JA, Fridlyand J, Kageshita T et al. Distinct sets of genetic alter-
ations in melanoma. N Engl J Med 2005; 353: 2135–2147.
16. Wan PT, Garnett MJ, Roe SM et al. Mechanism of activation of the RAF-
ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;
116: 855–867.
17. McArthur GA, Chapman PB, Robert C et al. Safety and efficacy of
vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma
(BRIM-3): extended follow-up of a phase 3, randomised, open-label
study. Lancet Oncol 2014; 15: 323–332.
18. Schadendorf D, Hodi FS, Robert C et al. Pooled analysis of long-term
survival data from phase II and phase III trials of ipilimumab in meta-
static or locally advanced, unresectable melanoma. J Clin Oncol 2015; 33:
1889–1904.
Annals of Oncology Original article
Volume 28 | Issue 10 | 2017 doi:10.1093/annonc/mdx339 | 2587
